[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Foundation Medicine, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":76},{"warningLetters":4,"total":75},[5,31,52],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2920,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-01-18T14:20:00Z\">01\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-16T05:00:00Z\">12\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffoundation-vapor-llc-623346-12162021\">Foundation Vapor LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David P. Norris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Foundation Vapor LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>225 South 19th Street, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Camp Hill\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17011\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:fveliquid@gmail.com\"> fveliquid@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 16, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Norris:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Foundation Vapor LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at&nbsp;\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section&nbsp;910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Foundation Vapor SourBerry Blast 3mg\u002Fml 100ml, Foundation Vapor Grape Pom 3mg\u002Fml 100ml, and Foundation Vapor Tropical Breeze 3mg\u002Fml 100ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 1,300 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100394, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDavid P. Norris\n\nRecipient Title\n\nOwner\n\nFoundation Vapor LLC\n\n225 South 19th Street, Suite 1\n\nCamp Hill, PA 17011\n\nUnited States\n\nfveliquid@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDecember 16, 2021\n\nWARNING LETTER\n\nDear Mr. Norris:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Foundation Vapor LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Foundation Vapor SourBerry Blast 3mg\u002Fml 100ml, Foundation Vapor Grape Pom 3mg\u002Fml 100ml, and Foundation Vapor Tropical Breeze 3mg\u002Fml 100ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 1,300 products listed with FDA. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100394, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Foundation Vapor LLC","foundation-vapor-llc-623346-12162021","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffoundation-vapor-llc-623346-12162021","2026-10-26T08:08:42.959768+00:00","Warning Letter","Issued","2022-01-18","623346","Tobacco","David P. Norris","2026-08-20T02:15:37.101+00:00","VIA UPS and Electronic Mail","2021-12-16",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},1509,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2024-04-23T13:20:00Z\">04\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-18T04:00:00Z\">04\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-sankunnis-ayurvedic-research-foundation-private-ltd-678046-04182024\">Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Register and List","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Samantha Ross\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11 East Park Road Shenoy Nagar\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chennai\u003C\u002Fspan> \u003Cspan>600030\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:registration@fdaimports.com\"> registration@fdaimports.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 18, 2024\u003Cbr>\n\u003Cbr>\nRE: WL 2643\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Ross:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm NDC, 70146-010; Womens Sports Balm, NDC 70146-011and Hand Sanitizer NDC 70146-012.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&amp;C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the previously mentioned drugs, the manufacturer referenced is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided December 15, 2022, to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not involved in manufacturing of the drugs mentioned above, and therefore, this firm should not be registered with FDA as a manufacturer. On March 6, 2023, OQS\u002FOPQ requested that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. deregister their establishment and delist all drug listings which reference Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. as the manufacturer. However, to date, no updates have been made to the listing files to correct the manufacturer’s name and the firm remains registered as a manufacturer. In addition, many of the listings mentioned above include other listing errors such as an incorrect dosage form, mismatched strength of an active ingredient, missing active ingredient, and incorrect label images. Therefore, these products are in violation of the following additional regulations under section 510(j)(1)(c) and 21 CFR 207.49(a)(6), 21 CFR 207.49 (a)(4) and 21 CFR 207.49(a)(15)(ii)(B). The table below includes products with associated listing errors.\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>NDC\u003C\u002Ftd>\n\t\t\t\u003Ctd>Proprietary Name\u003C\u002Ftd>\n\t\t\t\u003Ctd>Error(s) Found\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-000\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003Cbr>\n\t\t\t3.The labeling also includes a carton label image of another product which is not listed.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-001\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of the listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-002\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-003\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-004\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-005\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Sports Balm,\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-006\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-007\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. The listing SPL does not include the active ingredient methyl salicylate which is found in the labeling.\u003Cbr>\n\t\t\t3. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-008\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-009\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-010\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-011\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-012\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Hand Sanitizer\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm, NDC 70146-010; Womens Sports Balm, NDC 70146-011; and Hand Sanitizer NDC 70146-012 are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products included in the table above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2643 on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSamantha Ross\n\nDr Sankunni’s Ayurvedic Research Foundation Private Ltd.\n\n11 East Park Road Shenoy Nagar\n\nChennai 600030\n\nTamil Nadu\n\nIndia\n\nregistration@fdaimports.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nApril 18, 2024\n\nRE: WL 2643\n\nDear Ms. Ross:\n\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm NDC, 70146-010; Womens Sports Balm, NDC 70146-011and Hand Sanitizer NDC 70146-012.1 Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nRegistration and Drug Listing Violations\n\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the previously mentioned drugs, the manufacturer referenced is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided December 15, 2022, to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not involved in manufacturing of the drugs mentioned above, and therefore, this firm should not be registered with FDA as a manufacturer. On March 6, 2023, OQS\u002FOPQ requested that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. deregister their establishment and delist all drug listings which reference Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. as the manufacturer. However, to date, no updates have been made to the listing files to correct the manufacturer’s name and the firm remains registered as a manufacturer. In addition, many of the listings mentioned above include other listing errors such as an incorrect dosage form, mismatched strength of an active ingredient, missing active ingredient, and incorrect label images. Therefore, these products are in violation of the following additional regulations under section 510(j)(1)(c) and 21 CFR 207.49(a)(6), 21 CFR 207.49 (a)(4) and 21 CFR 207.49(a)(15)(ii)(B). The table below includes products with associated listing errors.\n\nNDC\nProprietary Name\nError(s) Found\n\n70146-000\n\nRelief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n3.The labeling also includes a carton label image of another product which is not listed.\n\n70146-001\n\nWomens Relief Balm\n\n1. Incorrect manufacturer included under the establishment section of the listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n70146-002\n\nSports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n70146-003\n\nWomens Sports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n70146-004\n\nRelief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-005\n\nSports Balm,\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-006\n\nWomens Relief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n70146-007\n\nWomens Sports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. The listing SPL does not include the active ingredient methyl salicylate which is found in the labeling.\n\n3. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-008\n\nRelief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-009\n\nSports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-010\n\nWomens Relief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-011\n\nWomens Sports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-012\n\nHand Sanitizer\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm, NDC 70146-010; Womens Sports Balm, NDC 70146-011; and Hand Sanitizer NDC 70146-012 are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products included in the table above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2643 on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________________\n\n1 On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).","Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.","dr-sankunnis-ayurvedic-research-foundation-private-ltd-678046-04182024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-sankunnis-ayurvedic-research-foundation-private-ltd-678046-04182024","2026-10-26T08:08:26.88063+00:00","2024-04-23","678046","Drugs","Samantha Ross","2026-08-20T00:09:54.678+00:00","2024-04-18",{"id":53,"raw":54,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":58,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":74,"medical_device_id":19,"response_letter_date":19},1388,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2024-07-09T13:20:00Z\">07\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-20T04:00:00Z\">06\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-mexico-lions-sight-conservation-foundation-inc-dba-new-mexico-lions-eye-bank-681776-06202024\">New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank\u003C\u002Fa>","Division of Biological Products Operations II","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey L. Millea\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2501 Yale Boulevard SE, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Jeffrey.Millea@corneagen.com\"> Jeffrey.Millea@corneagen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 20, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter OBPO 24-681776\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Millea:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, New Mexico Lions Sight Conservation Foundation, Inc., also doing business as New Mexico Lions Eye Bank, located at 2501 Yale Boulevard SE, Suite 100, Albuquerque, NM, conducted between February 23 and February 28, 2024, the United States Food and Drug Administration (FDA) documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21 Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)]. \u003C\u002Fstrong>You failed to determine as ineligible two donors of ocular HCT\u002FPs with a documented diagnosis or clinical evidence of sepsis, including two or more systemic responses to infection, documented within their available medical records during the hospital stay immediately preceding death. For example:\u003C\u002Fp>\n\n\u003Cp>a. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 2\u002F5\u002F24, and ocular HCT\u002FPs from the donor were distributed on 2\u002F1\u002F24.\u003C\u002Fp>\n\n\u003Cp>The donor was taken to the Emergency Department (ED) on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> and was found to have altered mental status, hypothermia, hypotension, leukocytosis, and lactic acidosis, among other serious medical conditions. The donor was diagnosed with urosepsis and treated with three renally dosed antibiotics and was admitted to the Intensive Care Unit (ICU) for sepsis and septic shock. The donor continued to decline and expired on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> had a diagnosis of sepsis (urosepsis), risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Urinary tract infection (urine culture from 1\u002F29\u002F24 grew more than 100,000 cfu\u002FmL of more than two microorganisms);\u003C\u002Fli>\n\t\u003Cli>Elevated White Blood Cell (WBC) count &gt;12,000 cells\u002Fmm\u003Csup>3\u003C\u002Fsup> (21,700 cells\u002Fmm\u003Csup>3\u003C\u002Fsup> on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Respiratory rate &gt;20 breaths\u002Fminute (26 breaths\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Heart rate &gt;90 beats\u002Fminute (99 beats\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Altered mental status;\u003C\u002Fli>\n\t\u003Cli>Lactic acidosis; and\u003C\u002Fli>\n\t\u003Cli>Hypotension.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> was determined eligible on 3\u002F6\u002F23, and ocular HCT\u002FPs from the donor were distributed on 3\u002F2\u002F23.\u003C\u002Fp>\n\n\u003Cp>The donor presented in the ED on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> with acute hypoxic respiratory failure, decreased tissue perfusion, tachycardia, tachypnea, and hypertension. Not long after arriving in the ED, the donor’s systolic blood pressure dropped in the 50s mmHg, which is described as the medical center’s “sepsis protocol.” Despite treatment with intravenous fluids, antibiotics, and norepinephrine, the donor continued to decline and expired on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>. According to documentation in the medical records, the donor’s primary cause of death is listed as septic shock, with a secondary cause of death as acute hypoxic respiratory failure.\u003C\u002Fp>\n\n\u003Cp>Donor \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong> had a diagnosis of sepsis and septic shock, risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>WBC count &gt;12,000 cells\u002Fmm\u003Csup>3\u003C\u002Fsup>, &lt;4,000 cells\u002Fmm\u003Csup>3\u003C\u002Fsup>, or band forms &gt;10% (donor had left shift of 88.3% neutrophils and 53% band forms on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Respiratory rate &gt;20 breaths\u002Fminute (36 breaths\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Heart rate &gt;90 beats\u002Fminute (137 beats\u002Fminute on \u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>);\u003C\u002Fli>\n\t\u003Cli>Elevated serum creatinine (2.4 mg\u002FdL on 2\u002F28\u002F23 (0.5-1.5mg\u002FdL reference range)) indicating acute kidney injury;\u003C\u002Fli>\n\t\u003Cli>Acute hypoxic respiratory failure;\u003C\u002Fli>\n\t\u003Cli>Altered mental status; and\u003C\u002Fli>\n\t\u003Cli>Systolic blood pressure dropped to 50 mmHg.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The events described above are HCT\u002FP deviations related to core Current Good Tissue Practice (CGTP) requirements and must be investigated and documented. Because these situations represent an HCT\u002FP deviation relating to a core CGTP and to the prevention of communicable disease transmission or HCT\u002FP contamination; and HCT\u002FPs were distributed, deviation reports must be submitted to FDA in accordance with 21 CFR 1271.350(b).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to ensure procedures are in compliance with the donor eligibility requirements within Subpart C – Donor Eligibility of 21 CFR Part 1271 [21 CFR 1271.47(a)].\u003C\u002Fstrong> For example, your procedures, “T-710 Donor Screening Criteria,” “TF-710-01 Donor Screening Criteria Guide,” and “T-720 Donor Eligibility Determination,” are used to determine donor eligibility, and “TF-710-02 Sepsis Algorithm,” is used to determine a donor’s risk for sepsis and if an infectious disease consult is required. These procedures fail to include all clinical evidence and systemic responses to infection, if unexplained, of sepsis during the donor’s hospital stay immediately preceding death to appropriately evaluate a donor’s sepsis risk. Additionally, your procedures fail to include systemic responses to infection of sepsis such as a heart rate &gt;90 beats\u002Fminute, partial pressure of carbon dioxide (PaCO2) &lt;32\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, and more severe signs of sepsis, such as unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension.\u003C\u002Fp>\n\n\u003Cp>Both donors referenced above were evaluated for a risk of sepsis using the “TF-710-02 Sepsis Algorithm.” Documentation in the donor records included the following standard statement that failed to take into account all the clinical evidence of sepsis and systemic responses to infection as documented in the medical records during the hospital stay immediately preceding death:\u003C\u002Fp>\n\n\u003Cp>“As long as these were all the clinical ID tests drawn (or the only ID studies done) (blood, sputum, urine, peritoneal fluid, CSF, AFB Cxs; viral tests; Quantiferon, etc) there was no definitive empirical evidence of sepsis or bacteremia at TOD.”\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter, dated March 20, 2024, providing a response to the FDA’s inspectional observations. We have reviewed your response and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response.\u003C\u002Fp>\n\n\u003Cp>1. In response to Observation 1, your disagreement that the donors were septic at the time of the death does not account for the donors’ medical records with documented diagnoses and clinical evidence of sepsis, including systemic responses to infection, during their hospital stay immediately preceding death. Your response states, “Quite simply, one cannot be septic and have negative blood cultures. And the practice of paper sepsis has proven over and over and over and over to be an inaccurate characterization of sepsis. At the same time the active problem list carries over “sepsis” the individual has no elevated temp and has 2 sets of no growth blood cultures. Prior to 2009, this individual would not have sepsis listed on their active problem list because the no growth blood cultures prove the patient is not septic! Fast forward to 2009 and a line has been drawn in the sand and most patients on admit are all of a sudden septic?! We respectfully challenge the FDA to please follow the logic here.”\u003C\u002Fp>\n\n\u003Cp>Regardless of the year, the donors would have been diagnosed with sepsis based on clinical presentation and laboratory data. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.\u003Csup>\u003Cem>\u003Cstrong>1-2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A diagnosis of sepsis can be made in the emergency room and positive blood cultures are not required for the diagnosis of sepsis.\u003Csup>\u003Cem>\u003Cstrong>1-2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Positive pre-mortem blood cultures \u003Cstrong>may\u003C\u002Fstrong> be associated with clinical evidence of sepsis. However, negative blood cultures do not exclude a diagnosis of bacteremia or sepsis. Routine blood cultures do not identify all microbial agents that can cause sepsis and additional incubation time, or special media is sometimes needed. Previous administration of antibiotics is frequently a reason for negative blood cultures (i.e., culture negative sepsis)\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. There are a myriad of reasons why blood cultures may be negative in cases of sepsis, and the absence of a positive blood culture does not exclude sepsis as a cause of death.\u003C\u002Fp>\n\n\u003Cp>Additionally, in FDA’s Guidance for Industry: Eligibility Determination of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (August 2007), the Agency describes our current thinking on the risks of sepsis in deceased donors to include a review of medical records during a hospital stay immediately preceding death for diagnosis of sepsis, clinical evidence of infection, and systemic responses to infection. These risk factors for sepsis and septic shock are supported in recent medical literature.\u003Csup>\u003Cem>\u003Cstrong>1-2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>2. Your response to Observation 2 states your current written procedures meet FDA regulatory requirements for evaluating clinical signs\u002Fsymptoms of sepsis. However, your procedures and algorithm do not account for the diagnosis or clinical evidence of sepsis, including systemic responses to infection, during a hospital stay immediately preceding death. They also do not include more severe signs of sepsis, for example, unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension per FDA guidance referenced above. We note that a donor must be determined ineligible if there is documented diagnosis and clinical evidence of sepsis, including systemic responses to infection, documented in their medical records during a hospital stay immediately preceding death regardless of whether that information is documented within five days of death.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction has been achieved. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 248-8146 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Evans, L. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11): e1063-e1143\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Scheer, CS. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. Clin Microbiol Infect. 2019 Mar; 25(3):326-331.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJeffrey L. Millea\n\nRecipient Title\n\nExecutive Director\n\nNew Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank\n\n2501 Yale Boulevard SE, Suite 100\n\nAlbuquerque, NM 87106\n\nUnited States\n\nJeffrey.Millea@corneagen.com\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nJune 20, 2024\n\nWarning Letter OBPO 24-681776\n\nDear Mr. Millea:\n\nDuring an inspection of your firm, New Mexico Lions Sight Conservation Foundation, Inc., also doing business as New Mexico Lions Eye Bank, located at 2501 Yale Boulevard SE, Suite 100, Albuquerque, NM, conducted between February 23 and February 28, 2024, the United States Food and Drug Administration (FDA) documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21 Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271) and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)]. You failed to determine as ineligible two donors of ocular HCT\u002FPs with a documented diagnosis or clinical evidence of sepsis, including two or more systemic responses to infection, documented within their available medical records during the hospital stay immediately preceding death. For example:\n\na. Donor (b)(6), (b)(7)(C) was determined eligible on 2\u002F5\u002F24, and ocular HCT\u002FPs from the donor were distributed on 2\u002F1\u002F24.\n\nThe donor was taken to the Emergency Department (ED) on (b)(6), (b)(7)(C) and was found to have altered mental status, hypothermia, hypotension, leukocytosis, and lactic acidosis, among other serious medical conditions. The donor was diagnosed with urosepsis and treated with three renally dosed antibiotics and was admitted to the Intensive Care Unit (ICU) for sepsis and septic shock. The donor continued to decline and expired on (b)(6), (b)(7)(C).\n\nDonor (b)(6), (b)(7)(C) had a diagnosis of sepsis (urosepsis), risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\n\nUrinary tract infection (urine culture from 1\u002F29\u002F24 grew more than 100,000 cfu\u002FmL of more than two microorganisms);\n\nElevated White Blood Cell (WBC) count >12,000 cells\u002Fmm3 (21,700 cells\u002Fmm3 on (b)(6), (b)(7)(C));\n\nRespiratory rate >20 breaths\u002Fminute (26 breaths\u002Fminute on (b)(6), (b)(7)(C));\n\nHeart rate >90 beats\u002Fminute (99 beats\u002Fminute on (b)(6), (b)(7)(C));\n\nAltered mental status;\n\nLactic acidosis; and\n\nHypotension.\n\nb. Donor (b)(6), (b)(7)(C) was determined eligible on 3\u002F6\u002F23, and ocular HCT\u002FPs from the donor were distributed on 3\u002F2\u002F23.\n\nThe donor presented in the ED on (b)(6), (b)(7)(C) with acute hypoxic respiratory failure, decreased tissue perfusion, tachycardia, tachypnea, and hypertension. Not long after arriving in the ED, the donor’s systolic blood pressure dropped in the 50s mmHg, which is described as the medical center’s “sepsis protocol.” Despite treatment with intravenous fluids, antibiotics, and norepinephrine, the donor continued to decline and expired on (b)(6), (b)(7)(C). According to documentation in the medical records, the donor’s primary cause of death is listed as septic shock, with a secondary cause of death as acute hypoxic respiratory failure.\n\nDonor (b)(6), (b)(7)(C) had a diagnosis of sepsis and septic shock, risk factors for and clinical evidence of sepsis, and two or more systemic responses to infection documented in the medical records of the hospital stay immediately preceding death based on, but not limited to, the following:\n\nWBC count >12,000 cells\u002Fmm3, \u003C4,000 cells\u002Fmm3, or band forms >10% (donor had left shift of 88.3% neutrophils and 53% band forms on (b)(6), (b)(7)(C));\n\nRespiratory rate >20 breaths\u002Fminute (36 breaths\u002Fminute on (b)(6), (b)(7)(C));\n\nHeart rate >90 beats\u002Fminute (137 beats\u002Fminute on (b)(6), (b)(7)(C));\n\nElevated serum creatinine (2.4 mg\u002FdL on 2\u002F28\u002F23 (0.5-1.5mg\u002FdL reference range)) indicating acute kidney injury;\n\nAcute hypoxic respiratory failure;\n\nAltered mental status; and\n\nSystolic blood pressure dropped to 50 mmHg.\n\nThe events described above are HCT\u002FP deviations related to core Current Good Tissue Practice (CGTP) requirements and must be investigated and documented. Because these situations represent an HCT\u002FP deviation relating to a core CGTP and to the prevention of communicable disease transmission or HCT\u002FP contamination; and HCT\u002FPs were distributed, deviation reports must be submitted to FDA in accordance with 21 CFR 1271.350(b).\n\n2. Failure to ensure procedures are in compliance with the donor eligibility requirements within Subpart C – Donor Eligibility of 21 CFR Part 1271 [21 CFR 1271.47(a)]. For example, your procedures, “T-710 Donor Screening Criteria,” “TF-710-01 Donor Screening Criteria Guide,” and “T-720 Donor Eligibility Determination,” are used to determine donor eligibility, and “TF-710-02 Sepsis Algorithm,” is used to determine a donor’s risk for sepsis and if an infectious disease consult is required. These procedures fail to include all clinical evidence and systemic responses to infection, if unexplained, of sepsis during the donor’s hospital stay immediately preceding death to appropriately evaluate a donor’s sepsis risk. Additionally, your procedures fail to include systemic responses to infection of sepsis such as a heart rate >90 beats\u002Fminute, partial pressure of carbon dioxide (PaCO2) \u003C321, and more severe signs of sepsis, such as unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension.\n\nBoth donors referenced above were evaluated for a risk of sepsis using the “TF-710-02 Sepsis Algorithm.” Documentation in the donor records included the following standard statement that failed to take into account all the clinical evidence of sepsis and systemic responses to infection as documented in the medical records during the hospital stay immediately preceding death:\n\n“As long as these were all the clinical ID tests drawn (or the only ID studies done) (blood, sputum, urine, peritoneal fluid, CSF, AFB Cxs; viral tests; Quantiferon, etc) there was no definitive empirical evidence of sepsis or bacteremia at TOD.”\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations as a whole to ensure that you are in compliance with the law.\n\nWe acknowledge receipt of your letter, dated March 20, 2024, providing a response to the FDA’s inspectional observations. We have reviewed your response and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response.\n\n1. In response to Observation 1, your disagreement that the donors were septic at the time of the death does not account for the donors’ medical records with documented diagnoses and clinical evidence of sepsis, including systemic responses to infection, during their hospital stay immediately preceding death. Your response states, “Quite simply, one cannot be septic and have negative blood cultures. And the practice of paper sepsis has proven over and over and over and over to be an inaccurate characterization of sepsis. At the same time the active problem list carries over “sepsis” the individual has no elevated temp and has 2 sets of no growth blood cultures. Prior to 2009, this individual would not have sepsis listed on their active problem list because the no growth blood cultures prove the patient is not septic! Fast forward to 2009 and a line has been drawn in the sand and most patients on admit are all of a sudden septic?! We respectfully challenge the FDA to please follow the logic here.”\n\nRegardless of the year, the donors would have been diagnosed with sepsis based on clinical presentation and laboratory data. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.1-2 A diagnosis of sepsis can be made in the emergency room and positive blood cultures are not required for the diagnosis of sepsis.1-2 Positive pre-mortem blood cultures may be associated with clinical evidence of sepsis. However, negative blood cultures do not exclude a diagnosis of bacteremia or sepsis. Routine blood cultures do not identify all microbial agents that can cause sepsis and additional incubation time, or special media is sometimes needed. Previous administration of antibiotics is frequently a reason for negative blood cultures (i.e., culture negative sepsis)3. There are a myriad of reasons why blood cultures may be negative in cases of sepsis, and the absence of a positive blood culture does not exclude sepsis as a cause of death.\n\nAdditionally, in FDA’s Guidance for Industry: Eligibility Determination of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (August 2007), the Agency describes our current thinking on the risks of sepsis in deceased donors to include a review of medical records during a hospital stay immediately preceding death for diagnosis of sepsis, clinical evidence of infection, and systemic responses to infection. These risk factors for sepsis and septic shock are supported in recent medical literature.1-2\n\n2. Your response to Observation 2 states your current written procedures meet FDA regulatory requirements for evaluating clinical signs\u002Fsymptoms of sepsis. However, your procedures and algorithm do not account for the diagnosis or clinical evidence of sepsis, including systemic responses to infection, during a hospital stay immediately preceding death. They also do not include more severe signs of sepsis, for example, unexplained hypoxemia, elevated lactate, oliguria, altered mentation, and hypotension per FDA guidance referenced above. We note that a donor must be determined ineligible if there is documented diagnosis and clinical evidence of sepsis, including systemic responses to infection, documented in their medical records during a hospital stay immediately preceding death regardless of whether that information is documented within five days of death.\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction has been achieved. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\n\nYour response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 248-8146 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\n_______________________\n\n1 Singer M, Deutschman CS, Seymour CW, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:801–810.\n\n2 Evans, L. et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11): e1063-e1143\n\n3 Scheer, CS. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. Clin Microbiol Infect. 2019 Mar; 25(3):326-331.","New Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank","new-mexico-lions-sight-conservation-foundation-inc-dba-new-mexico-lions-eye-bank-681776-06202024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-mexico-lions-sight-conservation-foundation-inc-dba-new-mexico-lions-eye-bank-681776-06202024","2026-10-26T08:09:32.559365+00:00","2024-07-09","681776","Biologics","Jeffrey L. Millea","2026-08-19T23:59:24.176+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-06-20",3,{"510k":77,"classification":78,"enforcement":79,"event":80,"event_backfill":81,"pma":82,"warning_letter":83},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]